Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Capital Expenditures (2017 - 2024)

Solid Biosciences' Capital Expenditures history spans 8 years, with the latest figure at -$450000.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures fell 600.0% year-over-year to -$450000.0; the TTM value through Sep 2024 reached $540000.0, down 76.33%, while the annual FY2023 figure was $1.5 million, 49.75% down from the prior year.
  • Capital Expenditures for Q4 2024 was -$450000.0 at Solid Biosciences, down from $430000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.6 million in Q3 2022 and bottomed at -$450000.0 in Q4 2024.
  • The 5-year median for Capital Expenditures is $264000.0 (2022), against an average of $353157.9.
  • The largest annual shift saw Capital Expenditures skyrocketed 2700.0% in 2022 before it crashed 600.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $60000.0 in 2020, then surged by 1460.0% to $936000.0 in 2021, then decreased by 8.55% to $856000.0 in 2022, then crashed by 89.49% to $90000.0 in 2023, then plummeted by 600.0% to -$450000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Capital Expenditures are -$450000.0 (Q4 2024), $430000.0 (Q3 2024), and $20000.0 (Q1 2024).